Page 48 - Haematologica - Vol. 105 n. 6 - June 2020

G. Pavlasova and M. Mraz
Venetoclax and obinutuzumab in patients with CLL and coexisting conditions. N Engl J Med. 2019;380(23):2225-2236.
117. Thijssen R, Slinger E, Weller K, et al. Resistance to ABT-199 induced by microen- vironmental signals in chronic lymphocytic leukemia can be counteracted by CD20 anti- bodies or kinase inhibitors. Haematologica. 2015;100(8):e302-e306.
118. Dimopoulos MA, Tedeschi A, Trotman J, et al. Phase 3 trial of ibrutinib plus rituximab in Waldenström’s macroglobulinemia. N Engl J Med. 2018;378(25):2399-2410.
119. Woyach JA, Blachly JS, Rogers KA, et al. Acalabrutinib plus obinutuzumab in treat-
ment-naïve and relapsed/refractory chronic lymphocytic leukemia. Cancer Discov. 2020;10(3):394-405.
120. Mounier N, El Gnaoui T, Tilly H, et al. Rituximab plus gemcitabine and oxaliplatin in patients with refractory/relapsed diffuse large B-cell lymphoma who are not candi- dates for high-dose therapy. A phase II Lymphoma Study Association trial. Haematologica. 2013;98(11):1726-1731.
121. Mankaï A, Buhé V, Hammadi M, et al. Improvement of rituximab efficiency in chronic lymphocytic leukemia by CpG- mediated upregulation of CD20 expression independently of PU.1. Ann N Y Acad Sci.
2009;1173:721-728.
122. Friedberg JW, Kim H, McCauley M, et al.
Combination immunotherapy with a CpG oligonucleotide (1018 ISS) and rituximab in patients with non-Hodgkin lymphoma: increased interferon-α/β–inducible gene expression, without significant toxicity. Blood. 2005;105(2):489-495.
123. Kozlova V, Ledererova A, Doubek M, Mayer J, Pospisilova S, Smida M. Epigenetic drug screen on resistant CLL cells reveals aurora kinase inhibitors as enhancers of CD20 expression and sensitizers to treat- ment with CD20 monoclonal antibodies. Blood. 2018;132(Suppl 1):4407.
1506
haematologica | 2020; 105(6)